Le Lézard
Classified in: Health

NEW JERSEY MARINE BECOMES PROCURE'S 7,000TH PATIENT TO COMPLETE CANCER TREATMENT


SOMERSET, N.J., May 8, 2024 /PRNewswire/ -- Retired New Jersey Marine Robert Hanley became the 7,000th patient to complete treatment at ProCure Proton Therapy Center, surpassing a major milestone at the tri-state region's original proton therapy facility.

Hanley was diagnosed with lung cancer in August 2023. His doctors at the VA originally recommended chemotherapy and traditional radiation, but they were concerned about the impact on his heart. His doctors turned to ProCure and proton therapy, in part because it could effectively address his cancer while reducing radiation exposure by up to 50% compared to standard X-ray radiation.

Standard X-ray radiation releases its maximum dose and continues to release it as it passes and exits through the body beyond the tumor. By contrast, proton therapy releases its maximum dose directly within the tumor and then stops, sparing nearby organs such as the heart.

Additionally, patients often experience fewer side effects both during and after treatment with proton therapy versus traditional radiation.

"ProCure gave me the chance to feel like myself again," Hanley said. "Thanks to this treatment and my amazing doctor and nurses, I am hopeful to be on a path to recovery."

"On behalf of the entire ProCure team, we want to thank Mr. Hanley for his service and dedication to our country," said Tom Wang, President of ProCure. "As a cancer patient and retired Marine, he exemplifies the core values of honor and courage. We are inspired that he put his trust in our team."

ProCure, located in nearby Somerset, NJ, treats a range of cancers, including diseases of the prostate, breast, lung, brain, head and neck, and gastrointestinal system, as well as sarcomas and many pediatric cases.

"We are honored to have impacted 7,000 lives and counting," said Dr. Brian Chon, ProCure's Medical Director, who treated Hanley. "Each patient's journey is a testament to our commitment to excellence and the transformative power of proton therapy. Our dedicated team at ProCure remains steadfast in our mission to provide exceptional care and innovative treatment options to those battling cancer."

Added Wang: "Surpassing this milestone has taken an extremely skilled care team, professional support team, and partnerships at area institutions that have collaborated with us throughout our journey. We are grateful to everyone who has contributed to these life-changing treatments and we look forward to continued innovation so we can serve patients for decades to come."

About ProCure Proton Therapy Center:

ProCure Proton Therapy Center in Somerset, NJ, opened in March 2012 as the tri-state region's first proton therapy facility, treating a range of cancers including diseases of the prostate, breast, lung, brain, head and neck, and gastrointestinal system, as well as sarcomas and many pediatric cases. Using the most advanced radiation treatment available, ProCure has treated more than 7,000 patients overall, including 750+ pediatric patients coming from the U.S. and abroad, and enables many cancer patients to choose a non-surgical treatment personalized to their medical needs and lifestyles, often with fewer side effects and less downtime?giving them more freedom to enjoy what matters most in their lives. For more information, visit ProCure.com.

Media Contact:
Sarah Ferrington, Marketing Manager
Phone: 732-357-2609
Email: [email protected]

SOURCE ProCure Proton Therapy Center


These press releases may also interest you

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...

at 12:18
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 11:10
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...



News published on and distributed by: